Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.
Miriam Chung, MD
Advertisement
Miriam Chung, MD, is an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai
Articles by Miriam Chung, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia
2
What New 26-Week COMP006 Data Mean for TRD, With Boadie Dunlop, MD
3
Daily Inhaled TPIP Improved PAH Measures at 12 Months in OLE
4
FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD
5